Zevra Therapeutics
Manufacturing · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1180 Celebration Blvd Ste 103, Celebrati...Phone Number
(888) 958-1253Website
www.zevra.comRevenue
$122.3 MillionStock Symbol
ZVRAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Zevra Therapeutics
Zevra Therapeutics, founded in 2006, is a pharmaceutical company specializing in rare disease therapeutics. The company focuses on developing life-changing treatments for patients with significant unmet medical needs. Zevra's approach involves collaboration with thought leaders, physicians, patients, and advocacy groups throughout clinical and regulatory development processes. The company utilizes innovative problem-solving methods to overcome complex development challenges in bringing therapies to market. With a data-driven methodology and transparent approach, Zevra Therapeutics works to make essential medications accessible to patients with rare conditions.Explore more
Zevra Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zevra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Zevra Therapeutics
Earning: See what the market has to say on Zevra Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Zevra Therapeutics has new funding data
Zevra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Zevra Therapeutics is spiking on competitors!
Check if Zevra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Zevra Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Zevra Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Zevra Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Zevra Therapeutics
Compare insights from companies similar to Zevra Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zevra Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zevra Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zevra Therapeutics.
Zevra Therapeutics financials insights
Gather financial insights about Zevra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$762K
2014
Debt
$50M
2015
Stock Offering
$56M
2016
Debt
$75M
2020
Debt
$350K
Zevra Therapeutics Tech Stack
A closer look at the technologies used by Zevra Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals
Hiring Plans
Zevra Therapeutics has more open roles in Medical & Health than it has had at any time in the past 6 months.
Hiring Plans
Open Position
Open Position
Open Position
Zevra Therapeutics News & Media
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient populationZevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)
Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potential securities law claims tied to the July 24, 2026 selloff. NEW YORK, July 27, 2026...Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAAZevra Therapeutics Announces Details for Q2 2026 Financial Results Call
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the second quarter on Wednesday, August 5, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zevra Therapeutics
Sign Up For FreeTo access detailed company insights
Zevra Therapeutics, founded in 2006, is a pharmaceutical company specializing in rare disease therapeutics. The company focuses on developing life-changing treatments for patients with significant unmet medical needs. Zevra's approach involves collaboration with thought leaders, physicians, patients, and advocacy groups throughout clinical and regu... Read More
